ARWR Maintained by JP Morgan -- Price Target Raised to $95.00
JP Morgan has maintained an "Overweight" rating for Arrowhead Pharmaceuticals Inc. (ARWR) and raised its price target from $88.00 to $95.00, signaling increased confidence in the company's future. Despite this, GuruFocus data indicates ARWR is currently overvalued by 46.4% based on its GF Value, …